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Summary.-Prognostic factors have been studied in 59 men with clinical Stage I
non-seminomatous germ-cell tumours of the testis (NSGCTT) seen at the Royal
Marsden Hospital between 1973 and 1978. Fourteen of the patients relapsed, and 45
have remained continuously disease-free. Two factors were identified which showed
a significant correlation with relapse following radiotherapy: local extent of the
primary tumour, and rate of decline of serum a-foetoprotein (AFP) and :-human
chorionic gonadotrophin (hCG) levels following orchidectomy. High serum marker
levels at the time of referral after orchidectomy were not prognostically significant
per se. The presence of tissue-associated hCG in the primary tumour was not prog-
nostically significant. The results were compared with histology and pathological
stage of the primary tumour in patients presenting with lung metastases but no
clinical evidence of lymph-node disease. Embryonal carcinoma was more commonly
associated with a locally invasive primary tumour and with extralymphatic spread
than was teratocarcinoma.
THE RESULTS OF TREATMENT at this
centre for patients with clinical Stage I
non-seminomatous germ-cell tumours of
the testis (NSGCTT) managed by elective
lymph-node irradiation following orchidec-
tomy have been reported previously
(Peckham, 1979). With this approach
- 20% of patients relapse, disease recur-
ring predominantly in the lungs and
supradiaphragmatic lymph nodes (Peck-
ham et al., 1977). The early detection of
relapse and prompt institution of chemo-
therapy results in excellent survival fig-
ures (Peckham et al., 1979, 1981). How-
ever, in order to avoid inessential therapy
it would be advantageous if the group of
patients with a high probability of relapse
after radiotherapy could be identified
prospectively.
It is known, from comparisons of lym-
phography with lymph-node histology,
that 250 ofclinicalStage Ipatients have
sub-clinical retroperitoneal node meta-
stases and that the probability of eradica-
ting them with radiotherapy is high
(Peckham et al., 1977). Growth-rate
measurements on lung metastases in
patients relapsing after irradiation suggest
that in most patients pulmonary spread
has occurred by the time of initial
diagnosis (Peckham et al., 1977). Com-
puterized axial X-ray tomographic (CAT)
scanning of the lungs will identify a
proportion, but not all, of this group
initially (Husband et al., 1981).
The prognostic significance of serum
o-foetoprotein (AFP) and f-human chori-
onic gonadotrophin (B-hCG) levels in
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early-stage patients managed with radio-
therapy has not hitherto been determined.
The extent of the primary tumour, re-
ported to be a significant prognostic factor
in the British Testicular Tumour Panel
series (Pugh & Cameron, 1976), has not
been adequately studied in carefully
staged patients.
The purpose of the analysis presented
here was to identify significant prognostic
factors in Stage I patients as a basis for
future management policy. The character-
istics of the primary tumour that might
predispose to haematogenous spread have
been further investigated by examining a
group of patients who presented with
clinically detectable lung metastases but
no evidence of lymph-node deposits.
PATIENTS AND METHODS
A total of 59 patients treated between
1973 and 1978 for histologically proven
NSGCTT and who, after an extensive
clinical evaluation, had no evidence of
metastases (Stage I) were included in the
study.
A second group of 21 men who presented
with obvious lung metastases but no clinical
evidence of lymph-node spread has been
analysed to see whether factors predisposing
to extralymphatic dissemination in Stage I
patients were common in patients assumed
to have haematogenous spread. This latter
group had Stage IVo L1, IVo L2, or IVo L3
disease according to the Royal Marsden
Hospital classification summarized below.
Clinical staging.-This included lymph-
ography, i.v. pyelography, chest X-ray and
whole-lung tomograms, liver, and retro-
peritoneal ultrasonic scans, liver-function
tests and, in selected patients, liver scinti-
scans. Since 1977, CAT scans of the lungs,
liver and retroperitoneum have been per-
formed routinely. Serum AFP and hCG
estimations were performed on referral, and
at each follow-up visit, using standard
radioimmunoassay techniques. Before 1974
urinary hCG estimations were performed.
Stage I patients in whom tumour markers
were not assayed within 6 weeks of orchi-
dectomy, or where there was over 2 months
delay between orchidectomy and radio-
therapy, were excluded from the study.
Stagingclassification.-Thisdescribes extent
of tumour, site(s) ofinvolvement and tumour
volume.
I. Lymphogram negative, no evidence of
metastases.
II. Lymphogram positive, metastases con-
fined to abdominal nodes. Three sub-groups
are recognized:
A. Maximum diameter of metastases<2 cm
B. Maximum diameter of metastases 2-5 cm
C. Maximum diameter of metastases >5 cm
III. Involvement of supra- and infra-
diaphragmatic lymph nodes. No extra-
lymphatic metastases. Abdominal status: A,
B, C as for Stage II.
IV. Extralymphatic metastases. Suffixes
as follows: o-lymphogram negative, A, B,
C as for Stage II. Lung status: L1 <3 metas-
tases. L2multiple, < 2 cmmaximumdiameter.
L3 multiple, one or more>2 cm diameter.
Liver status: H+ =liver involvement.
Three of the 4 following parameters should
be positive before liver involvement is
diagnosed.
1. Abnormal liver-function tests
2. Positive CT scan
3. Positive ultrasonic or isotopic scan
4. Clinical enlargement
Histology.-Thiswasreviewedinall patients
and details oflocal invasion and cord involve-
ment sought. The histological classification
was that proposed by the British Testicular
Tumour Panel (BTTP) (Pugh & Cameron,
1976) and included the following sub types:
Malignant teratoma undifferentiated (MTU)
[embryonal carcinoma]
Malignant teratoma intermediate (MTI) [tera-
tocarcinoma]
Malignant teratoma trophoblastic (MTT)
Teratoma differentiated (TD)
The presence of a seminoma component did
not modify the teratoma classification.
Pathological staging.-The local extent of
the primary tumour was classified using
the criteria of the BTTP (Pugh & Cameron,
1976) as follows:
P1: Tumour confined to testis or rete
P2: Tumour involving epididymis and/or
lower cord
P3: Tumour involving upper cord
Px: Staging not possible, inadequate hist-
ological material available.
Immunoperoxidase staining.-The indirect
immunoperoxidase technique was used for
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tissue staining for hCG (Heyderman &
Neville, 1976; Heyderman, 1977). Tropho-
blastic tissue was used as a positive control,
andnegative control wasachieved byensuring
complete extinction ofstaining by incubating
the anti hCG antisera with hCG before use.
Tissue staining for AFP was not assessed,
as most tissues had been fixed in formal
saline and, in our experience, standard
formalin fixation had been associated with a
highly variable immunoperoxidase staining
pattern for AFP, which we have been
unable to interpret with certainty.
Radiotherapy.-Stage I patients received
radiotherapy (6-8 MeV photons) by anterior
and posterior fields to the para-aortic and
ipsilateral iliac nodes, delivering mid-plane
doses of40-45 Gray in 4-5 weeks.
Statistical analysis.-This was performed
according to the techniques described by
Peto et al. (1976, 1977).
RESULTS
(A) Stage I patients
Patient age and side of the tumour.
The 59 males included in the study ranged
in age from 17-60 years (mean 29-6 years)
at presentation. The tumour was on the
left in 29 patients, right in 29 patients
and bilateral in 1 man. Side ofpresentation
and age did not influence outcome oftreat-
ment.
Histology of the primary tumour.-As
shown in Table I, 41/59 patients had MTI
and 18/59 MTU. No examples of MMT or
TD were seen in this series. The relapse
rate for MTU (5/18-27.8%) was slightly
but not significantly higher than that for
MTI (9/41-21.9%).
P stage of the primary tumour.-As
shown in Table I, P stage could be assessed
in 49 patients. The relapse rate in P1
tumours was 7/39 (17.9%) compared
with 6/10 (60%) for P2 and P3 tumours.
This difference is significant (P< 0 01).
Serum AFP and hCG levels.-As shown
in Table II, initial AFP values (in most
cases at referral after orchidectomy)
were raised in 18 patients (30.5%). Since
there was a mean delay of20 days between
orchidectomy and referral, and since the
serum-halving time of AFP is , 7 days,
TABLE I.-Clinical Stage I non-semino-
matous germ-cell tumours of the testis
(NSGCTT). Relapses according to histo-
logy ofprimary tumour and pathological
stage
Histology of
primary
tumourt
MTU
MTU/SEM
MTI
MTI/SEM
Total
Total
patients
14
4
26
15
59
Pathological stage
A
Pi P2P3 Px
1/7* 3/5 0/2
1/4 0/0 0/0
3/20 2/2 0/4
2/8 1/3 1/4
7/39 6/10 1/10
x2=7.-2
P<0.01
* Relapses/total at risk
t MTU=malignant teratoma undifferentiated
[embryonal carcinoma]
MTI=malignant teratoma intermediate [terato-
carcinoma]
SEM=seminoma
103
0
0
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E 102 -
n
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.
0
S
S
0
SO
0
I
Relapse Relapse-free
group group
OnTitre reported as>200
FiG. 1.-Initial serum ax-foetoprotein levels
and clinical status after radiotherapy in
clinical Stage I non-seminoma germ-cell
tumours of the testis (NSGCTT).
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TABLE II.-Serum marker status* at referral in clinical Stage I NSGCTT
Raised serum markers
A & -> Both
AFP AFP hCG markers
only (HCG not assayed) only AFP & hCG negative
13 (22%) 2 (3%) 2 (3%) 3 (5%) 34 (58%)
*hCG levels not assayed in 7 patients, 2 ofwhiom had raised AFP levels.
it is possible that the true percentage of
AFP-positive patients is higher. Serum
AFP levels ranged from 31 to 3000 p,g/l,
but there was no correlation between
serum level and prognosis. Of the 18
patients with raised AFP levels, 5 relapsed
(Fig. 1).
Only 5 (8.5%) men had raised hCG
levels (Table II), but since the normal
half-life of serum hCG is 24-36 h it is
highly probable that the true number with
raised hCG serum levels at the time of
orchidectomy was higher. In 3/5 hCG+
cases, assay was performed on the day
of orchidectomy.
Tissue HOG.-Tissue sections were
stained immunocytochemically for hCG
TABLE III.-C1linical Stage I NSGCTT
Serum hCG levels on referral in relation
to tissue hCG
Immunocytochemically
demonstrated tissue
hCG
+
ND
Serum hCG
High Low
3 21
1* 16
1 10
ND
3
4
0
* Possibly a sampling error: few sections available
for analysis.
in 48 patients, and were positive in 27
(56.2%). As shown in Table III, in 21
tissue-positive patients, serum hCG levels
were normal in 18 when they were refer-
red to the Royal Marsden Hospital. This
may well reflect rapid clearance from the
blood when the primary tumour is re-
moved. One tissue-negative patient
showed high serum levels ofhCG. Presence
ofhCG in tissue sections had no prognostic
significance. Six of 27 (22.2%) tissue-
positive patients relapsed, compared with
7/21 (33%) tissue-negative patients.
Changes in serum marker levels between
orchidectomy and radiotherapy.-As shown
in Table IV, patients were divided into
two groups, A and B.
In Group A there was evidence that
serum marker levels were either persis-
tently negative before irradiation or, if
high, they fell with a half-life consistent
with the removal of all the tumour
(AFP: 6-7 days, hCG: 24-36 h).
Group B included patients with persis-
tently high serum marker levels, and those
with a slow rate offall after orchidectomy.
If only one value was available several
weeks after orchidectomy and before
TABLE IV.-Clinical Stage I. Behaviour of serum markers after orchidectomy in relation
to relapse rate
Group
A
Criteria
Markers always negative,
or high marker at
orchidectomy falling with
normal half-life AFP 7 days
hCG < 36 h
B High marker level with
a) rate of fall protracted
or b) data not permitting rate
of marker fall to be
determined, but inconsistent
with rapid clearance
A vs B=P<001.
Number of
patients
49
No. of
relapsing
(%)
8 (16)
10 6 (60)
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Group A
I
Group B
o Relapse-free patient
* Relapsed patient
, I I , I I I
10 20 30 40 50 60 70 80 90
Months
F'IG. 2. Clinical Stage I NSGCTT. Contill-
uous (lisease-free survival by serum-markei
status. Group A = serum markers persis-
tently negative or if high before radiother-
apy fell rapidly after orchi(lectomy. Group
B =serum markers showing protracted fall
or persistent elevation below orchidectomy
andl irradiation. (The Royal Marsden
Hospital 1973-1978).
radiotherapy, it was assumed that com-
plete clearance following removal of the
primary tumour would not occur. Of the
total group, 6 patients had 2-6 measure-
ments and 4 patients had one.
In Group A, 8/49 (16K3%) patients
relapsed, compared with 6/10 (60%) of
50-
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Histology of Primary Tumour
Fio. :3.-Histology NSGCTT of the primary
tumour in relation to absenice (Stage I) or
presence (Stage IV) of pulmonary metast-
ases in patients writhl no chlinical ex-idernce of
lymplh no(le metastases.
UI
.4-)
:0
,0
Clinical Stage I
Clinical Stage IVoL 1-3
V P1 P2P3
Pathological Stage of Primary Tumour
Fic. 4. Histology NSGCTT of primary
tumour in relation to absence (Stage I) oI-
presence (Stage IV) of pulmonary meta-
stases in patients with no clinical evidence
of lymph-node metastases.
GIroup B patients. This difference is
significant (P < 001). The disease-free
survival curves are shown in Fig. 2.
Relapse pattern and patient survival.
Of the 14 patients who relapsed, the
pattern was as follows: left cervical
nodes (3), lung ± mediastinal nodes (7),
brain/lung (1), groin nodes (1), abdominal
nodes +extralymphatic metastases (2).
Seven patients were successfully treated
for relapse and 52/59 (88%0) ofthe patients
are alive and disease-free. There were
5 (8%) tumour deaths, I died of a cere-
brovascular accident and 1 of complica-
tions relating to chemotherapy.
(B) Stage I Vo Li L2 and L3 patients
This group was examined with respect
to histology and pathological stage of the
primary tumour, and compared with the
findings described above in Stage 1
disease.
Fig. 3 shows that, whereas in Stage I
there is a preponderance of MTI primary
tumours, the commonest sub-type in
IVO L1l3 is MTU.
As shown in Fig. 4, whereas there was
a preponderance of P1 tumours in Stage
100 -
o 75-
*@ 50-
0
N. 25 -
u
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I (30/49=79 6%) the converse was the
case in IVo L1l3, where 9/11 (82%) of
men in whom adequate material was
available for P stage to be established
showed evidence of cord invasion (P2P3).
If P stage and histology for Stage I and
IVo Ll 3 patients are considered together
(Fig. 5) it is seen that MTI tends to be
associated with Pi primary extent (28/35
-80%), whereas MTU shows a higher
tendency to involve the spermatic cord
(11/24-46%).
DISCUSSION
In an attempt to understand factors
influencing treatment outcome we have
studied 59 patients with clinical Stage
I NSGCTT managed by orchidectomy and
radiotherapy. Of these, 14 patients (240 °)
relapsed and 45 (76%) have remained
persistently disease-free.
Age at presentation and side of primary
tumour had no influence on relapse rate.
In previous analyses on a larger number
of patients the relapse rate for patients
with MTU primaries was significantly
greater than that for MTI (Peckham et
al., 1977). In the present smaller series
no significant difference was observed.
The observations made in Stage I patients
and patients presenting with lung meta-
stases and no evidence of lymph-node
disease indicate that MTU is associated
with a higher probability of cord involve-
ment than is MTI.
Extent of the primary tumour was a
significant prognostic factor, there being
an increased incidence of relapses in
patients with tumour involving spermatic
cord, epididymis or scrotal sac (P< 0 01).
This agrees well with the increased in-
cidence of P2 and P3 stages in a group of
patients presumed to have haemato-
genous spread without clinical evidence
of nodal deposits at presentation. An
important prognostic indicator in this
series was the rate of decline of serum
AFP and hCG levels after orchidectomy.
Thus the relapse rate in patients with
negative or rapidly falling markers was
significantly less than in patients with a
protracted decline (16% vs 60% res-
pectively; P < 0 01).
Becauseofthedelay in referral following
orchidectomy, the estimated incidences
of 30.500 for patients with high AFP levels
is probably artificially low, since the
half-life of serum AFP is 7 days.
Since the average delay in referral was 21
days, patients with pre-orchidectomy
levels of 25-200 tmg/l may have had
undetectable levels on referral. This
applies even more to hCG, the half-life
of which is 24-36 h. This may well explain
why only 3/27 patients with immuno-
cytochemically demonstrable hCG in pri-
mary tumour tissue had high serum hCG
levels on referral. The frequency of hCG+
tissue (56.2%) may reflect the proportion
of patients with elevated serum hCG
levels more accurately. The presence of
immunocytochemically demonstrable hCG
did not influence prognosis. Similarly, no
significant difference was observed in
rates of relapse between patients with
initially normal and high serum marker
levels (Fig. 1). However, because of the
delay in most patients between orchi-
dectomy and first assay, and the possi-
bility that a proportion of men with nor-
mal serum marker levels at referral may
have had high levels at orchidectomy,
the true significance of serum-marker
status cannot be fully assessed.
The present study has the disadvantage
of being a retrospective analysis of a
relatively small number of patients who
were eligible for inclusion. Nevertheless,
it seems clear that extent of primary
tumour and serum marker behaviour
after orchidectomy are important factors
which discriminate between patients with
low and high risk of extralymphatic dis-
semination. In Stage I patients with
persistent serum markers there is a high
risk of extralymphatic disease, and the
treatment of choice is chemotherapy.
In patients free of adverse prognostic
factors, the relapse rate after lymph-node
irradiation is low, and the overall cure
rate high if relapses are detected early
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and treated promptly with chemotherapy
(Pechkam et al., 1979, 1981). On the other
hand, it seems probable that at least 75%
ofmen with Stage I disease and no adverse
prognostic factors may be cured by orchi-
dectomy alone. In 1979 radiotherapy was
abandoned in this group of patients in
favour of a policy of careful follow-up
after orchidectomy. To date, of 21 men
followed up for at least a year, 4 (19%)
have relapsed. All relapses have occurred
within 6 months of orchidectomy, and
have only been seen in patients with
MTU (embryonal carcinoma). All 4 re-
lapsed patients have been successfully
treated with chemotherapy for small-
volume disease. The objective of the sur-
veillance study is to define prognostic
factors accurately, in order to provide a
rational basis for future management.
In the retrospective analysis which is
described in this report we were unable
with confidence to distinguish P2 from P3
tumours, because of limited pathological
material. For this reason, unless there is
tumour in the proximal spermatic cord,
patients are not excluded from the sur-
veillance study. Other potentially import-
ant factors, such as lymphatic permeation
and vascular invasion within the primary
tumour, are being investigated in con-
junction with a more detailed study of
blood and tissue markers.
The authors wish to thank Professor K. D.
Bagshawe and Miss A. H. Orr for assaying hCG
and AFP levels.
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